Catalent (CTLT)
(Delayed Data from NYSE)
$56.16 USD
+0.02 (0.04%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $56.17 +0.01 (0.02%) 5:28 PM ET
5-Strong Sell of 5 5
F Value D Growth D Momentum F VGM
Brokerage Reports
Catalent, Inc. [CTLT]
Reports for Purchase
Showing records 81 - 100 ( 217 total )
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Early FY23 Guidance Shows Path Beyond COVID
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Bioproduction: Catalent''s $350M Indiana Expansion Signals Growth
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
2022 Life Sciences and MedTech Conference: Day 2 Takeaways
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Growth Exceeds; Nuggets Around COVID, 483, Cell Therapy Outlook; Read-Throughs
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Goldilocks Ignored - JPM Week and Implications for Coverage List
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Transformational Year Validating Higher Industry Growth
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Wegovy for Novo Nordisk Appears Immaterial and No Vaccine/ Therapy Implications
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department